EDITAS MEDICINE, INC. Accretion (Amortization) of Discounts and Premiums, Investments
EDITAS MEDICINE, INC. (EDIT) reported Accretion (Amortization) of Discounts and Premiums, Investments of $4.92 million for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-11-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments · last filed 2024-11-04
- EDITAS MEDICINE, INC. accretion (amortization) of discounts and premiums, investments for the quarter ending 2024-09-30 was $1.33M, a 6.34% increase year-over-year.
- EDITAS MEDICINE, INC. accretion (amortization) of discounts and premiums, investments for the quarter ending 2024-06-30 was $1.88M, a 141.03% increase year-over-year.
- EDITAS MEDICINE, INC. accretion (amortization) of discounts and premiums, investments for the quarter ending 2024-03-31 was $1.72M, a 147.62% increase year-over-year.
- EDITAS MEDICINE, INC. accretion (amortization) of discounts and premiums, investments for the quarter ending 2023-09-30 was $1.25M.
| Period end | Accretion (Amortization) of Discounts and Premiums, Investments 3 month | Accretion (Amortization) of Discounts and Premiums, Investments 6 month | Accretion (Amortization) of Discounts and Premiums, Investments 9 month |
|---|---|---|---|
| 2024-09-30 | $1.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | $3.21M derived: sum of 2 quarters · filed 2024-11-04 | $4.92M 10-Q · filed 2024-11-04 |
| 2024-06-30 | $1.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $3.60M 10-Q · filed 2024-08-07 | |
| 2024-03-31 | $1.72M 10-Q · filed 2024-05-08 | ||
| 2023-09-30 | $1.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | $2.03M derived: sum of 2 quarters · filed 2024-11-04 | $2.72M 10-Q · filed 2024-11-04 |
| 2023-06-30 | $780.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $1.47M 10-Q · filed 2024-08-07 | |
| 2023-03-31 | $693.00K 10-Q · filed 2024-05-08 | ||
| 2022-09-30 | $226.00K 10-Q · filed 2023-11-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |